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NEWSLETTER

Role of Pharmacist During the COVID‐19
Pandemic
In December 2019, a respiratory illness due to a novel coronavirus, SARS‐
CoV‐2, was first identified in China. The respiratory illness due to SARS‐
CoV‐2, termed COVID‐19, is now a worldwide pandemic and has been
identified in more than 200 countries and almost one million people.
Common symptoms of COVID‐19 include cough, shortness of breath, and
fever; disease ranges in severity from asymptomatic infection, mild disease
(in 81% of patients), to pneumonia, respiratory failure, and death.
The inability to test widely and quickly has hindered the ability to
characterize the epidemiology of the disease, prevent further spread, and
ensure the optimal use of other limited resources such as personal protective
equipment (PPE) and medication therapy. Pharmacists play an essential and
unique role within the healthcare team to optimize patient care during this
COVID‐19 pandemic.
Antiviral stewardship is vital during the pandemic. In lieu of antivirals
with established efficacy for COVID‐19, novel experimental agents are
currently being evaluated in controlled studies globally for the prophylaxis
and treatment of COVID‐19. Naturally, pharmacists are essential in
facilitating investigational drug studies in health systems but they are also
integral to helping obtain medication through compassionate use protocols.
While investigational drug pharmacists play a significant role here,
active involvement of those practicing in infectious diseases, information
technology, critical care, distribution, and management can streamline the
process and speed the time to therapy for study patients.
While no agents are currently FDA‐approved for treatment of COVID‐19,
a number of drugs approved for other indications are of great interest
for repurposing for COVID‐19 treatment, such as lopinavir/ritonavir,
chloroquine, and hydroxychloroquine; or may be immune‐modulating
agents, such as tocilizumab or interferons. If these agents are used, it is the
pharmacist’s role to provide accurate data to the providers about safe drug
delivery (eg, how to formulate oral drugs when patients cannot swallow),
drug‐drug interactions, and adverse effects. Patients also need appropriate
counseling about their use and potential harms, especially if use in the
community becomes widespread.
One of the fundamental role of pharmacist is to ensure the availability
and timely provision of the safest and most effective therapy. In this role,
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pharmacists must plan for, identify and mitigate drug shortages during the COVID‐19 pandemic. This is
crucial given that drug shortages can lead to prescribing of suboptimal therapy and have been associated with
patient harm. When there are limited suppliers of raw materials or active pharmaceutical ingredients (API),
drug shortages easily occur. Therefore, pharmacists must work pro-actively to identify effective therapeutic
alternatives, enforce the implementation of drug shortage mitigation strategies, and if needed, prioritize drug
supply to the patients who are most likely to benefit. Examples of safe usage, formulary restriction for COVID‐19
therapies that are in limited supply (ie, hydroxychloroquine) have educated providers about the restrictions, and
have implemented electronic alerts to prescribers upon ordering.
Pharmacists can take steps to minimize unnecessary PPE use by helping limit unnecessary entry into the patient
room. This can be done by aligning medication administration times, IV to PO switching when possible to
decrease nurses needing to respond to pump alerts, and ensuring lab draws, including therapeutic drug monitoring
are necessary and if possible are timed with other patient interactions. We can also limit staff to aerosolized
exposure of the virus by developing treatment protocols that limit unnecessary nebulizer use and instead favor
use of metered dose inhalers for inpatients. Furthermore, medication teaching of patients who are COVID‐19‐
positive or persons under investigation for COVID‐19 can be facilitated by telehealth approaches to minimize
exposure to pharmacists.
Lastly, pharmacists are a trusted and accessible resource for the public during this public health emergency,
especially community pharmacists. Pharmacists must educate their patients and the public on effective strategies
to prevent acquisition and further spread of infection (eg, optimal hand hygiene, social distancing, staying home
if having respiratory symptoms), symptomatic relief, and the best resources for current COVID‐19 information.
In conclusion, the genesis of the COVID‐19 pandemic occurred less than 4 months ago, our knowledge about
the disease is changing daily, and it is uncertain how long the pandemic will last. Pharmacists play a key role as
the drug information expert in evaluating literature related to new or repurposed therapies and can help make
system‐level and patient‐specific treatment decisions, as well as ensure access to these therapies and other drugs
on shortage due the pandemic.
References:

•
•
•

National Institutes of Health U.S. National Library of Medicine. Adaptive COVID‐19 Treatment Trial
Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020.
accpjournals.onlinelibrary

ASK AWAY
You may get an experts opinion by consulting with one of our specialist. Send in your questions at drug.information@aku.edu

OUR PANEL:
Clinical Pharmacy Specialists

Stewardship of Off-Label Treatments for COVID-19| An Evidence
Based Practice
The COVID-19 pandemic has become a public health emergency. While researchers are working to find a
treatment for the infection, no medication is currently approved by any international regulators like USFDA to
treat COVID-19. Some already approved medications for other indications are being tried as off-label treatments
of COVID-19.
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The Pharmacy & Therapeutics Committee (P&TC) in line with current international literature suggested some
recommendations as a general guide for prescribers and pharmacists when considering the appropriate use of
experimental treatments. These especially include Azithromycin, Chloroquine, and Hydroxychloroquine, and
oseltamivir.
Recommendation 1: Any prescription or medication order for a drug that is also being investigated for
the off-label treatment of COVID-19 should be reviewed for appropriateness.
1. Patients who are already prescribed these medications for non-COVID-19 indications should continue to
have access through new prescriptions or refills of existing prescriptions.
2. Outpatient prescriptions for these medications should include a documented diagnosis from the prescriber
with the FDA-approved indication or other literature-supported, off-label use.
3. Pharmacists should verify new prescriptions for these medications are appropriate, recognizing that patients
newly diagnosed with conditions like rheumatoid arthritis or lupus may be initiating treatment during the
coming weeks or months.
Recommendation 2: Prescriptions or medication orders for the off-label treatment of confirmed COVID-19
patients should be prioritized for inpatient use and limited in duration of treatment.
1. Decisions to use off-label medications to treat confirmed COVID-19 patients should be made by the
interprofessional team after weighing supporting evidence, risks, and potential benefits.
2. Informed consent describing the existing evidence, risks, and potential benefits should be established
between providers and patients, caregivers.
3. If patients initiated on treatment during inpatient admission must continue treatment upon discharge,
prescriptions should be coordinated through direct communication with an outpatient pharmacy.
4. Outpatient prescriptions should be dispensed only:
a.
b.
c.
d.

In coordination with discharge planning from an inpatient setting for continuity of care, or
For patients with a confirmed positive test for SARS-CoV-2.
Outpatient prescriptions should be limited to no more than a fourteen-day supply.
Refills should not be permitted.

Recommendation 3: Inventory of drugs being studied for the treatment of COVID-19 should be maintained
responsibly.
1. Pharmacies, especially outpatient pharmacies, should not attempt to buy up and hoard inventories that
will be most appropriately used in inpatient settings.
2. These medications should be stored with limited access.
For details of treatment options under research is available on Page 4 & 5

( Anti-malarial)

Only limited clinical
trial data available to
date to support use
of chloroquine or
hydroxychloroquine
for treatment or
prevention of
COVID-19 Multiple
clinical trials initiated
using various dosages
in pts with COVID-19
in China and other
countries.
Clinical experience in
pts with COVID-19
accumulating; reports
of possible clinical
benefits, including
decrease in viral
load and duration of
illness; only limited
data available to date
to support efficacy
and identify possible
safety concerns in pts
with COVID-19.

Trial or clinical
experience
Various dosages recommended or being
investigated.
Oral chloroquine phosphate: 500 mg twice
daily for 10 days
Oral chloroquine phosphate: 500 mg twice
daily for 7 days (adults 18-65 years weighing
>50 kg); 500 mg twice daily on days 1 and 2,
then 500 mg once daily on days 3-7 (adults
weighing <50kg).
Oral chloroquine phosphate: Initial dose of
600 mg (of chloroquine) followed by 300
mg (of chloroquine) 12 hours later on day 1,
then 300 mg (of chloroquine) twice daily on
days 2 to 5.
Consider: 500 mg of chloroquine phosphate
is equivalent to 300 mg of chloroquine base
Oral hydroxychloroquine: 400 mg twice
daily on day 1, then 200 mg twice daily on
days 2 to 5.
Oral hydroxychloroquine: 400 mg daily for
5 days
Oral hydroxychloroquine: 100-200 mg twice
daily for 5-14 days
Oral hydroxychloroquine: 200 mg 3 times
daily for 10 days

Dosage

ASHP-Guidelines on Off-Labelled Treatments for COVID-19

In vitro activity against
some viruses, including
coronaviruses. Chloroquine:
In vitro activity against
SARS-CoV-2 in infected
Vero E6 cells reported;
some evidence it may block
infection in Vero E6 cells
exposed to SARSCoV-2.
Chloroquine: Active in vitro
against SARS-CoV and
MERS-CoV.
Chloroquine: Active in vitro
against SARS-CoV and
MERS-CoV.
Hydroxychloroquine: In vitro
activity against SARSCoV-2
reported; additional study
needed, but may be more
potent than chloroquine
in vitro 8 Both drugs
have immunomodulatory
activity that theoretically
could contribute to an
antiinflammatory response in
patients with viral infections.
Known pharmacokinetics and
toxicity profile.

Chloroquine
Phosphate

Hydroxychl
oroquine

Rationale

Antivirals

Efficacy of chloroquine or
hydroxychloroquine for
treatment or prevention of
COVID-19 not established.
Additional data needed to
determine whether in vitro
activity against SARSCoV-2
corresponds with clinical efficacy for treatment or prevention of COVID19.
Additional data needed to
substantiate initial reports of
efficacy and identify optimal
dose and duration.
Chloroquine and hydroxychloroquine are suggested
as possible options and are
included in some guidelines
for treatment of COVID-19

Comments

The information contained in this evidence table is emerging and rapidly evolving because of ongoing research and is
subject to the professional judgment and interpretation of the practitioner due to the uniqueness of each medical facility’s
approach to the care of patients with COVID-19 and the needs of individual patients.

Assessment of Evidence for COVID-19-Related Treatments
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Antivirals active against
influenza viruses

Oseltamivir

In a retrospective case
series of 99 patients
with COVID-19
at single center in
Wuhan from 1/1/20
to 1/20/20, 76% of
patients received
antiviral treatment,
including oseltamivir
(75 mg orally every
12 hours). At the time
of evaluation, 58%
of patients remained
hospitalized, 31% had
been discharged, and
11% had died.
While oseltamivir
is noted to have
been widely used
for confirmed or
suspected COVID-19
cases in hospitals in
China, there has been
no exact evidence to
date that oseltamivir
is effective in
the treatment
of COVID-19.
Neither oseltamivir
nor zanamivir
has demonstrated
inhibition of
cytopathic effect
against SARS-CoV in
in vitro cell culture.

Trial or clinical
experience
Dosage of oseltamivir in the case series of
99 patients was 75 mg orally every 12 hours.
Dosages of oseltamivir from registered trials
(either recruiting, or not yet recruiting) vary,
but include 300 mg orally daily, 75 mg orally
once or twice daily, and 4–6 mg/kg orally
(frequency not specified).

Dosage

ASHP-Guidelines on Off-Labelled Treatments for COVID-19

Rationale

Antivirals
No data to date support use in
the treatment of COVID-19.

Comments
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Drug Interaction Update
Hafsah Ashfaq, Clinical Pharmacist
Hydroxychloroquine (HCQ) and Chloroquine are the antimalarial agents and has a new emerging role in

treatment of COVID-19 Pneumonia (Off-label). There is a French study showing the combination of HCQ
and azithromycin to prevent bacterial Super infections. Despite its small sample size the survey shows that
hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19
patients and its effect is reinforced by azithromycin. Both these drugs are associated with significant adverse
effects, hepatotxicity and risk of sudden death, especially when used with Azithromycin may enhance the overall
QTc prolongation. So it is recommended use with caution and monitoring. Additionally, elderly patients with
other serious underlying diseases, who are already vulnerable to complications from COVID-19 infection, may
be at higher risk for cardiac and hepatic side effects from these agents.
For details visit ;
Gautret et al. (2020) Hydroxychloroquine and azithromycin as a treatment of  COVID‐19: results of an open‐label non‐
randomized clinical trial. International Journal of Antimicrobial Agents – In Press 17 March 2020 – DOI : 10.1016/j.ijantimicag.2020.105949

ToxTalk | Bleach Ingestion
Faqeeha Shakeel, Pharmacist

Household poisons are substances in your home that can cause harm when swallowed, ingested, inhaled
or touched. They include cleaning products, detergents, medicines and other common household products.
Poisoning occurs most often in toddlers when children are exploring things at home. It’s usually common in
children less than 5 years of age.
In Pakistan, there are hoards of chemicals and cleaning agents available in the market in polythene bags and
unlabelled containers that leads to the poisoning of such chemicals in the children. Most household bleach
solutions contain 3% to 5% hypochlorite. Below mentioned is one of the case that Drug & Poison Information
Centre (DPIC) Pharmacist dealt with.
Call at Drug & Poison Information Center.
A Physician from a local Hospital called at Drug & Poison Information Centre ( DPIC) – AKUH for the
management of a poisoning case where a child chewed household bleach containing polythene bag.
According to her the Patient was vitally stable but unable to talk and open
his mouth because of swelling on lips and mouth. They have given single
dose of Inj. Pheniramine and Inj. Hydrocortisone. But not observed much
improvement. Our DPIC Pharmacist, advice physician to dilute with small
amounts of milk or water. Activated charcoal is CONTRAINDICATED.
Local application of anesthehic agent ( Lidocaine 2%) on the lips and
around the mouth with a cotton is advised and continue with the injections of antihistamine, Pheniramine.
Followup :
Our DPIC Pharmacist as a regular practice has taken the followup. As per the Physician, the patient symptoms
remarkably reduced and swelling returned to normal.
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Tips to Prevent Household Poisoning- Keep Child Safe.
•
•
•
•
•

•

Store chemicals and cleaners out of sight and reach of children at all times.
Don’t keep the chemicals into used juice or soft drink bottles.
Put all chemicals and cleaners away
immediately after finishing the use.
Safe disposal of chemicals when used is
necessary.
Never put cocroach powders or rat poison
on the floors of your home. Do not use
insect sprays on furniture or mattresses.
Keep laundry and dishwasher supplies out
of sight and in a locked cabinet.

References:

Micromedex – Toxicology
Pediatric toxicology; a publication of NPIS London.

If you think your child has swallowed something poisonous, call the Drug & Poisons Information
Centre on 021-34861504/1506 immediately.

COVID-19- Recommended Practices.
The virus appears to require close contact for human-to-human
transmission (i.e., within 6 feet) and primarily spreads via
droplets released when someone sneezes or coughs.
Take steps to protect yourself

Clean your hands often






Wash your hands with soap and water for at least 20 seconds 		
frequently especially after you have been in a public place, or
after blowing your nose, coughing, or sneezing.
If soap and water are not readily available, use a hand sanitizer
that contains at least 60% alcohol. Cover all surfaces of your 		
hands and rub them together until they feel dry.
Cough or Sneeze into your Sleeve.
Avoid touching your eyes, nose, and mouth with unwashed hands.
Immediately discard used tissues.

Practice social distancing,





Walk apart from one another.
Avoid close contact with people who are sick.
Avoid hand shake.
Be aware of where you place your hands and body.
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Drug Induced Nutrient & Vitamin Deficiency
Bilal Ahmad- Pharmacist

Introduction: Therapy optimization and reducing drug related harms is a critical and in-depth process to improve
patient safety and health quality. The pharmacist reviews the medication order for appropriateness to rule out
and minimize drug-drug and drug-food interactions, which lead to nutrients depletion-vital for physiological
functions. Drug utilization review is an optimal approach in community setting to identify address and intervene
the issue. The topic will highlight the major contributing medications lead to deficiency.
Common Drug-Nutrient Depletions

Nutrient

Formulary Supplements

Calcium

Syrup. Calcium carbonate
Qalsan-D, Chewcal, CAC1000 & Boncal plus.

Coenzyme Q10

Tab 30mg

Folic Acid

Tab. Folic Acid 5mg

Magnesium

Syp. Magnesium Chloride
Inj. Magnesium Sulphate

Vitamin B6

Tab. Vita-6 50mg

Thiamine

Tab & Inj. Neurobion ( Vit B1, B6 and B12)

Potassium

Tab. Neo-K 500mg (6.7mEq) Syp. Potassium chloride
13.33mEq/5ml Inj. Potassium chloride (1mEq/ml)

Vitamin A

Cap. 10,000, 100,000 and 200,000 units
Syp. 5000/5ml, Drops. 2666IU/drop Tab. 2500 IU

Vitamin B12

Methycobal® Tab & Inj 500 mcg

Vitamin K

Tab & inj 10mg

Vitamin D

Capsules (50k & 2lac, tablets (2000IU), Drops 400IU
and Injection (2 &6 lac).

Zinc

Syp 20mg/5ml 110 & 220mg Cap (compounded)

Recommendations for pharmacists:
o Pharmacist is required to review the order and identify the risk factors for nutrient depletion.
o
o
o
o
o

Underlying deficiency need to be evaluated for primary reasons.
To minimize the drug-food interaction, suggest gap between food and dose to be taken.
To evaluate the need for replacement, or can be overcome by diet.
Serum levels should be suggested before therapeutic replacement.
Counsel the patient, about the ways to minimize risk factors.

Provide us your Valuable Feedback!

To keep the Pharmacy Newsletter of Aga Khan University Hospital (AKUH) updated we would like to take your valuable feedback. We are grateful
to you for sparing few minutes of your precious time to complete form by below online link or form can be emailed to you as well. Just drop us an
email with subject Newsletter Feedback. Email us at:drug.information@aku.edu
For Formulary supplements assistance visit http://portal.aku.edu/pharmacy/olf.asp or Call 1504/1506
Thank you in advance for your feedback! Link: https://forms.gle/FCo9ZuE4CConzFp46

The Aga Khan University Hospital, Karachi

